Preview

Meditsinskiy sovet = Medical Council

Advanced search

PRIORITIES OF EARLY PATHOGENETIC THERAPY OF FLUE AND SARS OF OTHER ETIOLOGY

https://doi.org/10.21518/2079-701X-2016-15-78-82

Abstract

The prevalence of influenza and acute respiratory viral infections, high frequency of complications with a high mortality rate in certain groups of the population, short duration of specific immunity and the lack of efficiency of use of antiviral drugs for the treatment of patients make the problem of rational pathogenetic therapy of respiratory infections extremely urgent. The excessive local inflammatory reaction in response to the penetration of the pathogen of SARS in the body can lead to massive death of the tissue and rapid systemic spread of the infectious agent. Treatment of patients with influenza should be based on the likely dynamics of the onset of symptoms, development of complications and severe disturbances of the vital organs.
According to the principle of step by step treatment, any «influenza infection» must be regarded as a potentially serious illness that threatens the patient serious complications. Even with normal flu symptoms from the first hours from the onset of the disease, it is advisable to prescribe combination of the antiviral and pathogenetic therapy. A combination of antiviral, antipyretic, anti-inflammatory and antioxidant therapy at an early stage in most cases allows limitation of the development of severe forms of the disease and death prevention.

About the Authors

V. V. TSVETKOV
Scientific and Research Institute of Flu of the Ministry of Health of Russia
Russian Federation


G. S. GOLOBOKOV
Scientific and Research Institute of Flu of the Ministry of Health of Russia
Russian Federation


References

1. Национальное научное общество инфекционистов: Клинические рекомендации: острые респираторные вирусные заболевания у взрослых. 2014.

2. Львов Н.И., Писарева М.М., Мальцев О.В., Бузицкая Ж.В., Афанасьева В.С., Михайлова М.А., и др. Особенности этиологической структуры ОРВИ в отдельных возрастных и профессиональных группах населения Санкт-Петербурга в эпидемический сезон 2013–2014 гг. Журнал инфектологии, 2014, 6(3): 62-70.

3. Роспотребнадзор о завершении эпидемического сезона по гриппу и ОРВИ 2015–2016: http://rospotrebnadzor.ru/about/info/news/news_details.php?ELEMENT_ID=5995.

4. Denholm JT, Gordon CL, Johnson PD et al. Hospitalised adult patients with pandemic (H1N1) 2009 influenza in Melbourne, Australia. MJA, 2010, 192(2): 84-86.

5. Haaheim EdL, Pattison J, Whitley R. A practical guide to clinical virology. John Wiley and Sons, 2001.

6. Fernandez-Sesma A, Marukian S, Ebersole BJ et al. Influenza Virus Evades Innate and Adaptive Immunity via the NS1 Protein. J. Virol, 2006, 80: 6295-6304.

7. Жаркова Н.Е. Симптоматическое лечение ОРВИ: будущее за комбинированными препаратами. РМЖ, 2007, 22: 1636.

8. Bertin L et al. Randomised, double-blind, multicenter, controlled trial of ibuprofen versus acetaminophen (paracetamol) and placebo for treatment of symptoms of tonsillitis and pharyngitis in children. Journal of Pediatrics, 1991, 119(5): 811-4.

9. Bertin L et al. A randomised, double-blind, multicentre controlled trial of ibuprofen versus acetaminophen and placebo for symptoms of acute otitis media in children. Fundam Clin Pharmacol, 1996, 10: 387-92.

10. DornellesPicon P, Boff Costa M, da VeigaPicon R, Costa Cabral Fendt L, Carissimi Schmidt LF. Symptomatic treatment of the common cold with a fixed-dose combination of paracetamol, chlorphenamine and phenylephrine: a randomized, placebo-controlled trial. BMC Infect Dis, 2013, 13: 556.

11. Lauder SN, Taylor PR, Clark SR, Evans RL, Hindley JP, Smart K et al. Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity. Thorax, 2011, 66: 368-374.

12. Isbister GK, Prior F, Kilham HA. Restricting cough and cold medicines in children. Journal of Paediatrics and Child Health, 2012, 48: 91-98.

13. Atkinson HC, Stanescu I, Salem II, Potts AL, Anderson BJ. Increased bioavailability of phenylephrine by co-administration of acetaminophen: results off our open-label, crossover pharmacokinetic trials in healthy volunteers. Eur J ClinPharmacol, 2015, 71(2): 151-8.


Review

For citations:


TSVETKOV VV, GOLOBOKOV GS. PRIORITIES OF EARLY PATHOGENETIC THERAPY OF FLUE AND SARS OF OTHER ETIOLOGY. Meditsinskiy sovet = Medical Council. 2016;(15):78-82. (In Russ.) https://doi.org/10.21518/2079-701X-2016-15-78-82

Views: 1258


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)